Vitiligo

Was ist neu?

Vitiligo

What is new?

Zusammenfassung

Vitiligo betrifft 1 von 200 Menschen in Nordeuropa. Die Krankheit erzeugt großen Leidensdruck bei Betroffenen. Die Patienten leiden unter massiver H2O2- und Peroxinitrit-induzierter Redoximbalance mit nachgewiesener DNS-Schädigung in der Haut und im Blut, die in der Folge viele verschiedene körpereigene Signale betrifft. Der Nachweis von konstant hochreguliertem funktionierendem p53 wird als Reparaturmöglichkeit vorgestellt. Es wird versucht, mögliche Autoimmunreaktionen im Zusammenhang mit diesem Geschehen und genetischer Prädisposition/Spontanmutation zu erklären. Weiterhin werden verschiedene Therapieansätze inklusive Reduktion des oxidativen Stresses mit Pseudokatalase PC-KUS und kombinierte Klimatherapie sowie Verhaltensempfehlungen für den Patienten unter besonderer Berücksichtigung der neuen Erkenntnisse diskutiert.

Abstract

Vitiligo occurs in Northern Europe in one of 200 people. The disease can cause significant psychological stress for the affected individual. These patients generate and accumulate massive amounts of H2O2- and peroxynitrite in the epidermal compartment. Consequently many proteins are oxidized or nitrated, leading in turn to partial or complete loss of functionality. Moreover, presence of DNA damage in the skin as well as in plasma has been shown, while apoptosis is not enhanced. Induction of DNA repair is associated with up-regulated functioning p53 protein. Considering possible genetic predisposition and /or spontaneous mutations, autoimmune reactions in the disease are put forward in the context of oxidative stress. In addition a review of recent and novel treatment modalities including the role of oxidative stress reduction and combined climatotherapy at the Dead Sea in a group are discussed.

This is a preview of subscription content, log in to check access.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7

Literatur

  1. 1.

    Boersma BR, Westerhof W, Bos JD (1995) Repigmentation in vitiligo vulgaris by autologous minigrafting: results in nineteen patients. J Am Acad Dermatol 33:990–995

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Buckley DA, Rogers S (1996) Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo. Clin Exp Dermatol 21:43–45

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Chiaverini C, Passeron T, Ortonne JP (2002) Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 16:137–138

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Calanchini-Postizzi E, Frenk E (1987) Long-term actinic damage in sun-exposed vitiligo and normally pigmented skin. Dermatologica 174:266–271

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Casp CB, She JX, McCormack WT (2002) Genetic association of the catalase gene (CAT) with vitiligo susceptibility. Pigment Cell Res 15:62–66

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Dell’Anna ML, Picardo M (2006) A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo Pigment Cell Res 19:406–411

    Google Scholar 

  7. 7.

    Even-Paz Z (1996) Dermatology at the Dead Sea Spas. Isr J Med Sci 32(Suppl):11–15

    Google Scholar 

  8. 8.

    Gauthier Y, Cario-Andre M, Taieb A (2003) A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 16:322–332

    Article  PubMed  Google Scholar 

  9. 9.

    Grimes PE, Elkadi T, Sanders J (1999) Epstein-Barr virus infection in patients with vitiligo (abstr). J Invest Dermatol 112:604

    Google Scholar 

  10. 10.

    Grimes PE, Soriano T, Dytoc MT (2002) Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 47:789–791

    Article  PubMed  Google Scholar 

  11. 11.

    Howitz J, Brodthagen H, Schwartz M, Thomsen K (1977) Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 113:47–52

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Jin Y, Mailloux CM, Gowan K et al (2007) NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 356(12):1216–1225

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP (2007) Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev 6(3):138–142

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Krüger C, Smythe JW, Spencer JD et al (2010) Combined climatotherapy at the Dead Sea significantly improves quality of life and supports coping with the disease in patients with vitiligo. Acta Derm Venereol (submitted)

  15. 15.

    Kushelevsky AP, Slitkin MA (1975) Ultraviolet measurements at the Dead Sea and Beersheba. Isr J Med Sci 11:488–490

    CAS  PubMed  Google Scholar 

  16. 16.

    Neumeister P, Strunk D, Apfelbeck U et al (2000) Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma. Lancet 355(9212):1334–1350

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Njoo MD, Spuls P, Bos JD et al (1998) Nonsurgical repigmentation therapies in vitiligo – meta-analysis of the literature. Arch Dermatol 134:1532–1540

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Oyarbide-Valencia K, Boorn JG van den, Denman CJ et al (2006) Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev 5(7):486–492

    Article  PubMed  Google Scholar 

  19. 19.

    Papadopoulos L, Bor R, Legg C, Hawk JL (1998) Impact of life events on the onset of vitiligo in adults: preliminary evidence for a psychological dimension in a etiology. Clin Exp Dermatol 23:243–248

    Article  CAS  PubMed  Google Scholar 

  20. 20.

    Papadopoulos L, Bor R, Legg C (1999) Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol 72(Pt3):385–396

    Article  PubMed  Google Scholar 

  21. 21.

    Salem MM, Shalbaf M, Gibbons NC et al (2009) Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage. FASEB J 23(11):3790–3807

    Article  CAS  PubMed  Google Scholar 

  22. 22.

    Salzer BA, Schallreuter KU (1995) Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism. Dermatology 190:109–115

    Article  CAS  PubMed  Google Scholar 

  23. 23.

    Schallreuter KU (1999) Verdammte weiße Flecken. University of Bradford, Bradford, UK

  24. 24.

    Schallreuter KU (1995) Beta adrenergic blocking agents can provoke vitiligo. Br J Dermatol 132(1):168–169

    Article  CAS  PubMed  Google Scholar 

  25. 25.

    Schallreuter KU, Chiuchiarelli G, Cemeli E et al (2006) Estrogens can contribute to hydrogen peroxide generation and quinone-mediated DNA damage in peripheral blood lymphocytes from patients with vitiligo J Invest Dermatol 126:1036–1042

    Google Scholar 

  26. 26.

    Schallreuter KU, Bahadoran P, Picardo M et al (2008) Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 17:139–140

    CAS  PubMed  Google Scholar 

  27. 27.

    Schallreuter KU, Krüger C, Würfel BA et al (2008b) From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol 47(7):743–753

    Article  PubMed  Google Scholar 

  28. 28.

    Schallreuter KU, Lemke R, Brandt O et al (1994) Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology 188:269–275

    Article  CAS  PubMed  Google Scholar 

  29. 29.

    Schallreuter KU, Levenig C, Berger J (1991) Vitiligo and cutaneous melanoma. A case study. Dermatologica 183:239–245

    Article  CAS  PubMed  Google Scholar 

  30. 30.

    Schallreuter KU, Moore J, Behrens-Williams S et al (2002) Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol 41:482–487

    Article  PubMed  Google Scholar 

  31. 31.

    Schallreuter KU, Rokos H (2007) From the bench to the bedside: Proton pump inhibitors can worsen vitiligo. Br J Dermatol 156:1362–1402

    Article  Google Scholar 

  32. 32.

    Schallreuter KU, Tobin DJ, Panske (2002) A decreased photo damage and low incidence of non-melanoma skin cancer in 136 sun-exposed Caucasian patients with vitiligo. Dermatology 204:194–201

    Article  CAS  PubMed  Google Scholar 

  33. 33.

    Schallreuter KU, Wood JM, Pittelkow MR et al (1994) Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Science 263:1444–1446

    Article  CAS  PubMed  Google Scholar 

  34. 34.

    Schallreuter KU, Zschiesche M, Moore J et al (1998) In vivo evidence for compromised phenylalanine metabolism in vitiligo. Biochem Biophys Res Commun 243:395–399

    Article  CAS  PubMed  Google Scholar 

  35. 35.

    Spritz R, Fain P, Bennett D (2003) The epidemiology and genetics of generalized vitiligo. Pigment Cell Res 16:589–590

    Article  Google Scholar 

  36. 36.

    Spritz RA, Gowan K, Bennett DC, Fain PR (2004) Novel vitiligo susceptibility loci on chromosomes 7 (AIS2) and 8 (AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet 74:188–191

    Article  CAS  PubMed  Google Scholar 

  37. 37.

    Tosti A, Bardazzi F, De Padova MP et al (1986) Deafness and vitiligo in an Italian family. Dermatologica 172:178–179

    Article  CAS  PubMed  Google Scholar 

  38. 38.

    Wagoner MD, Albert DM, Lerner AB et al (1983) New observations on vitiligo and ocular disease. Am J Ophthalmol 96:16–26

    CAS  PubMed  Google Scholar 

  39. 39.

    Westerhof W, Nieuweboer-Krobotova L (1997) Treatment of vitiligo with UVB radiation vs topical psoralen plus UVA. Arch Dermatol 133:1525–1528

    Article  CAS  PubMed  Google Scholar 

  40. 40.

    Wood JM, Gibbons NC, Chavan B, Schallreuter KU (2008) Computer simulation of heterogeneous single nucleotide polymorphisms in the catalase gene indicates structural changes in the enzyme active site, NADPH-binding and tetramerization domains: a genetic predisposition for an altered catalase in patients with vitiligo? Exp Dermatol 17(4):366–371

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung hin: Die Pseudokatalase-Therapie wird bisher nur im Institut für Pigmentationsstörungen e.V. in Assoziation mit der Ernst Moritz Arndt Universität Greifswald und der University of Bradford/UK durchgeführt.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Prof. Dr K.U. Schallreuter.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schallreuter, K., Salem, M. Vitiligo. Hautarzt 61, 578–585 (2010). https://doi.org/10.1007/s00105-009-1916-9

Download citation

Schlüsselwörter

  • Vitiligo
  • Oxidativer Stress
  • DNA-Schaden
  • p53
  • Repigmentierung

Keywords

  • Vitiligo
  • Oxidative stress
  • DNA damage
  • p53
  • Repigmentation